Abstract
MVASI is a biosimilar to bevacizumab, a recombinant immunoglobulin G1 monoclonal antibody binding the vascular endothelial growth factor. Following comprehensive analytical characterization, MVASI was shown to be comparable to the reference product bevacizumab. It became one of the first therapeutic biosimilars approved by Health Canada for the treatment of all previously approved bevacizumab indications, including metastatic colorectal cancer (mCRC). To address Canadian healthcare stakeholders’ focus on real-world evidence generation for oncology biosimilars, this study aims to characterize Canadian mCRC patients treated with MVASI and to describe the real-world safety and effectiveness of MVASI.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
